The efficacy of chemotherapy on UCSD is not known. This study was conducted to investigate the efficacy of cisplatin-based chemotherapy and prognosis of patients with UC with or without SD of the bladder.
Patients with invasive bladder cancer (clinical T3-4aN0M0) who were treated between March 2003 and March 2015 with 2 or 3 cycles of neoadjuvant chemotherapy followed by radical cystectomy were retrospectively evaluated. Treatment outcomes were compared for each pathologic type in UCSD and pure UC. The primary end point was pathologic response in the cystectomy specimens. Disease-free survival and overall survival were secondary end points.
We evaluated 9 patients with UCSD and 29 patients with pure UC. In the cystectomy specimens, pathologic complete response without residual tumors was not seen in any patients with UCSD, but evident in 10 patients (34.5%) with pure UC. The proportion of pathologic downstaging was significantly lower in patients with UCSD than in those with pure UC (11.1% vs. 51.7%; P = .031). Patients with UCSD had poorer disease-free survival (P < .001) and overall survival (P = .001) than those with pure UC. On multivariate Cox regression analysis, SD in UC was an independent predictor of recurrence (hazard ratio, 4.43; 95% confidence interval, 1.44-13.6, P = .009) and mortality (hazard ratio, 3.51; 95% confidence interval, 1.11-11.1, P = .032).
UCSD of the bladder is less sensitive to cisplatin-based chemotherapy and has poor prognosis.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Genitourinary Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Urothelial carcinoma with squamous differentiation—the pathologists perspective.Urol Oncol. 2015; 33: 437-443
- Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital.Urol Oncol. 2013; 31: 1650-1655
- Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy.J Urol. 2012; 187: 74-79
- The effect of squamous and/or glandular differentiation on recurrence, progression and survival in urothelial carcinoma of bladder.Int Urol Nephrol. 2007; 39: 803-807
- The impact of variant histology on the outcome of bladder cancer treated with curative intent.Urol Oncol. 2009; 27: 3-7
- Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications.Mod Pathol. 2009; 22: S96-S118
- Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications.Hum Pathol. 2006; 37: 1371-1388
- The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy.Int Braz J Urol. 2007; 33: 339-346
- Clinical and therapeutic significance of aberrant differentiation pattern in bladder cancer.Expert Rev Anticancer Ther. 2007; 7: 1015
- Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy.Eur J Cancer. 2013; 49: 1889-1897
- Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis.Urol Oncol. 2014; 32: 117-127
- Surgical management of bladder urothelial carcinoma with squamous differentiation.Urol Oncol. 2015; 33: 429-433
- Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.N Engl J Med. 2003; 349: 859-866
- Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?.Eur Urol. 2013; 64: 355-357
- Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.Eur Urol. 2017; 71: 462-475
- Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.J Clin Oncol. 2016; 34: 1945-1952
- Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiation.Urol Oncol. 2015; 33: 434-436
- Clinical outcomes after neoadjuvant chemotherapy and radical cystectomy in the presence of urothelial carcinoma of the bladder with squamous or glandular differentiation.Clin Genitourin Cancer. 2016; 14: 82-88
- Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.Eur Urol. 2012; 61: 1229-1238
- Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).BJU Int. 2011; 108: 693-699
- Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.Ann Oncol. 2014; 25: 1192-1198
- Local recurrence after radical cystectomy for invasive bladder cancer.Urology. 2004; 64: 744-748
- Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.Eur Urol. 2014; 65: 350-357
- Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.J Urol. 1985; 134: 460-464
- Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.J Clin Oncol. 1997; 15: 2564-2569
- Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.Cancer. 2002; 95: 751-757
- The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy.Anticancer Res. 2006; 26: 3865-3869
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.J Clin Oncol. 1992; 10: 1066-1073
- Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer.J Urol. 2007; 177: 1287-1293
Published online: July 21, 2017
Accepted: July 18, 2017
Received in revised form: July 13, 2017
Received: April 29, 2017
© 2017 Elsevier Inc. All rights reserved.